FDA

We are now being encouraged by regulators worldwide to re-think our approach to monitoring and apply risk-based monitoring strategies rather than continue with our more traditional approaches.

The statistics show that fewer and fewer physicians are willing to take part in trials and that around half of those that do so once never do so again.

Debate rages on, European Parliament set to decide on new clinical trial rules in late October.

There are scarce or illdefined national and international regulations on quality control and standardization of biorepositories.

The clinical trial debate in the European Parliament is bogged down by rival schools of thought.

Consistent, effective process improvement can be the key to reducing delays and improving data accuracy.

European Commission's proposed system faces scrutiny from three separate committees.

Researchers from sub-Saharan countries are going to have better chances of upgrading their skills.

Decision makers can increase collaboration, transparency, efficiency, and effectiveness, while reducing development risks.

The EMA's predictions are a measure of optimism against a rather somber background.

Standard operating procedures need to be in place for the handling of suspected research misconduct.

Investigator training should not be a "one-off" session at the start of clinical trial.

Healthcare is seen as one of the most promising sectors to help boost EU employment.

Will ethics committees buy into the radical new approach of latest draft regulation?

A framework is needed to facilitate, promote, and reward basic and applied research for adults and children.

An analysis of warning letters and the findings reported from 1996 to 2010.

The European Union is preparing a report on the lessons learned from its 2006 pediatric regulation.

An entire section of Horizon 2020 is devoted to health, demographic change, and well-being.

Clinical trials community reacts favorably to tentative set of new rules, yet questions remain.

Proposed rule changes on public information in Europe never make it to fruition.

Biosimilars are a steadily growing new field of biopharmaceutical development and clinical research.

European Parliament voted against clearing the agency's accounts because of management concerns.

Multiple proposals for streamlining research emerge in legislation, expert reports.

Clinical trials should meet ethical and GCP standards no matter where in the world they are conducted.